Reports - Biomarker Market
Biotechnology and Life SciencesBiomarker Market
Biomarker Market Size & Share | Growth Analysis 2035 by Types (Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamic Biomarkers, Prognostics Biomarkers, Validation Biomarkers) by Applications (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, Others) by Product (Consumable, Services, Software) by Disease (Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Others) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Biomarker Market - Segment Analysis
1. Overview
2. Global Biomarker Market, 2020 - 2032 (USD Million)
3. Global Biomarker Market - by Types
3.1. By Safety Biomarkers
3.2. By Efficacy Biomarkers
3.3. By Predictive Biomarkers
3.4. By Surrogate Biomarkers
3.5. By Pharmacodynamic Biomarkers
3.6. By Prognostics Biomarkers
3.7. By Validation Biomarkers
4. Global Biomarker Market - by Applications
4.1. By Diagnostics
4.2. By Drug Discovery & Development
4.3. By Personalized Medicine
4.4. By Disease Risk Assessment
4.5. By Others
5. Global Biomarker Market - by Product
5.1. By Consumable
5.2. By Services
5.3. By Software
6. Global Biomarker Market - by Disease
6.1. By Cancer
6.2. By Cardiovascular Diseases
6.3. By Neurological Diseases
6.4. By Immunological Diseases
6.5. By Others
7. Global Biomarker Market - by region
7.1. North America
7.2. Europe
7.3. Asia Pacific
7.4. Latin America
7.5. Middle East & Africa
8. Market comparative analysis
Chapter 4 North America Biomarker Market - Segment Analysis
1. Overview
2. North America Biomarker Market, 2020 - 2032 (USD Million)
3. North America Biomarker Market - by Types
3.1. By Safety Biomarkers
3.2. By Efficacy Biomarkers
3.3. By Predictive Biomarkers
3.4. By Surrogate Biomarkers
3.5. By Pharmacodynamic Biomarkers
3.6. By Prognostics Biomarkers
3.7. By Validation Biomarkers
4. North America Biomarker Market - by Applications
4.1. By Diagnostics
4.2. By Drug Discovery & Development
4.3. By Personalized Medicine
4.4. By Disease Risk Assessment
4.5. By Others
5. North America Biomarker Market - by Product
5.1. By Consumable
5.2. By Services
5.3. By Software
6. North America Biomarker Market - by Disease
6.1. By Cancer
6.2. By Cardiovascular Diseases
6.3. By Neurological Diseases
6.4. By Immunological Diseases
6.5. By Others
Chapter 5 Europe Biomarker Market - Segment Analysis
1. Overview
2. Europe Biomarker Market, 2020 - 2032 (USD Million)
3. Europe Biomarker Market - by Types
3.1. By Safety Biomarkers
3.2. By Efficacy Biomarkers
3.3. By Predictive Biomarkers
3.4. By Surrogate Biomarkers
3.5. By Pharmacodynamic Biomarkers
3.6. By Prognostics Biomarkers
3.7. By Validation Biomarkers
4. Europe Biomarker Market - by Applications
4.1. By Diagnostics
4.2. By Drug Discovery & Development
4.3. By Personalized Medicine
4.4. By Disease Risk Assessment
4.5. By Others
5. Europe Biomarker Market - by Product
5.1. By Consumable
5.2. By Services
5.3. By Software
6. Europe Biomarker Market - by Disease
6.1. By Cancer
6.2. By Cardiovascular Diseases
6.3. By Neurological Diseases
6.4. By Immunological Diseases
6.5. By Others
Chapter 6 Asia Pacific Biomarker Market - Segment Analysis
1. Overview
2. Asia Pacific Biomarker Market, 2020 - 2032 (USD Million)
3. Asia Pacific Biomarker Market - by Types
3.1. By Safety Biomarkers
3.2. By Efficacy Biomarkers
3.3. By Predictive Biomarkers
3.4. By Surrogate Biomarkers
3.5. By Pharmacodynamic Biomarkers
3.6. By Prognostics Biomarkers
3.7. By Validation Biomarkers
4. Asia Pacific Biomarker Market - by Applications
4.1. By Diagnostics
4.2. By Drug Discovery & Development
4.3. By Personalized Medicine
4.4. By Disease Risk Assessment
4.5. By Others
5. Asia Pacific Biomarker Market - by Product
5.1. By Consumable
5.2. By Services
5.3. By Software
6. Asia Pacific Biomarker Market - by Disease
6.1. By Cancer
6.2. By Cardiovascular Diseases
6.3. By Neurological Diseases
6.4. By Immunological Diseases
6.5. By Others
Chapter 7 Latin America Biomarker Market - Segment Analysis
1. Overview
2. Latin America Biomarker Market, 2020 - 2032 (USD Million)
3. Latin America Biomarker Market - by Types
3.1. By Safety Biomarkers
3.2. By Efficacy Biomarkers
3.3. By Predictive Biomarkers
3.4. By Surrogate Biomarkers
3.5. By Pharmacodynamic Biomarkers
3.6. By Prognostics Biomarkers
3.7. By Validation Biomarkers
4. Latin America Biomarker Market - by Applications
4.1. By Diagnostics
4.2. By Drug Discovery & Development
4.3. By Personalized Medicine
4.4. By Disease Risk Assessment
4.5. By Others
5. Latin America Biomarker Market - by Product
5.1. By Consumable
5.2. By Services
5.3. By Software
6. Latin America Biomarker Market - by Disease
6.1. By Cancer
6.2. By Cardiovascular Diseases
6.3. By Neurological Diseases
6.4. By Immunological Diseases
6.5. By Others
Chapter 8 Middle East & Africa Biomarker Market - Segment Analysis
1. Overview
2. Middle East & Africa Biomarker Market, 2020 - 2032 (USD Million)
3. Middle East & Africa Biomarker Market - by Types
3.1. By Safety Biomarkers
3.2. By Efficacy Biomarkers
3.3. By Predictive Biomarkers
3.4. By Surrogate Biomarkers
3.5. By Pharmacodynamic Biomarkers
3.6. By Prognostics Biomarkers
3.7. By Validation Biomarkers
4. Middle East & Africa Biomarker Market - by Applications
4.1. By Diagnostics
4.2. By Drug Discovery & Development
4.3. By Personalized Medicine
4.4. By Disease Risk Assessment
4.5. By Others
5. Middle East & Africa Biomarker Market - by Product
5.1. By Consumable
5.2. By Services
5.3. By Software
6. Middle East & Africa Biomarker Market - by Disease
6.1. By Cancer
6.2. By Cardiovascular Diseases
6.3. By Neurological Diseases
6.4. By Immunological Diseases
6.5. By Others
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. F. Hoffmann-La Roche AG
2. Epigenomics AG
3. Abbott
4. Thermo Fisher Scientific Inc
5. General Electric
6. Eurofins Scientific
7. Johnson & Johnson Services Inc.
8. QIAGEN
9. Bio-Rad Laboratories Inc.
10. Siemens Healthineers AG
11. Merck KGaA
12. PerkinElmer Inc.
13. Agilent Technologies Inc.
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By